747 – Brain-Derived Neurotrophic Factor and B-Cell Lymphoma Leukemia-2 Plasma Levels in Patients with Subsyndromal Symptomatic Depression

Abstract

Objective:

To explore the relationship between brain-derived neurotrophic factor (BDNF) and B-cell lymphoma Leukemia-2 (Bcl-2) plasma levels in subsyndromal symptomatic depression (SSD) patients.

Methods:

In this case-control study, Enzyme-Linked Immunosorbnent Assay (ELISA) method was used to analysed the differences of BDNF plasma levels between SSD group (n=42) and healthy controls (n=51). At the same time Hamilton Depression Rating Scale-17(HAMD17) were assessed the patients'severity.

Result:

There were significant difference of BDNF plasma levels between SSD group (medium 2.97 ng/ml)and healthy group (medium 3.71ng/ml, z=-2.94, P 0.003). Furthermore, BDNF plasma levels in SSD patients were associated with Hamilton score (r -0.53, P < 0.001). Plasma Bcl-2 levels were not different between SSD group (medium 4951 U/ml) and health controls (medium 5574 U/ml) (z = -1.71, P =0.09); and plasma Bcl-2 levels in SSD group were not associated with Hamilton score (r -0.10, P 0.34).

Conclusion:

The study suggested that the decreased BDNF plasma levels were related with the pathophysiology of SSD and it might reflect the severity of disorder.